{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:16:21Z","timestamp":1793333781733,"version":"4.5.0"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Nuclear receptor binding SET domain protein 2 (NSD2) significantly contributes to the development of cancer, making it a promising target for cancer drug discovery. This research explores natural compounds as potential selective inhibitors for NSD2 in cancer treatment. Employing a comprehensive <jats:italic>in silico<\/jats:italic> approach, the study utilized pharmacophore modeling, molecular docking, pharmacokinetic profiling, and molecular dynamics simulations. An e-pharmacophore model-based screening using the first selective and potent ligand bound to NSD2 identified 49,248 natural compounds from the SuperNatural 3.0 database (containing 449,008 molecules) with acceptable alignment with the developed pharmacophore hypotheses. Subsequently, molecular docking was executed to assess the standout compounds which led to the selection of ten candidates that surpassed the reference inhibitor in accordance w the binding affinity expressed as a G score. Ligand-residue interaction analyses of the top three hits (SN0450102, SN0410255, and SN0142336) revealed diverse crucial interactions with the NSD2 active site, including hydrogen bonds, pi-pi stacking, and hydrophobic contacts with key amino acid residues in the NSD2-PWWP1 domain. Pharmacokinetic profiling confirmed the drug-likability for the refined hits, indicating good cellular permeability and minimal blood-brain barrier penetration. Molecular dynamics simulations for 200 nanoseconds affirmed the stability of protein-ligand complexes, with minimal fluctuations in root mean square deviation and root mean square fluctuation analyses. Overall, this study identified promising natural compounds as potential pharmaceutical agents in the treatment of NSD2-associated cancers.<\/jats:p>","DOI":"10.1371\/journal.pone.0308913","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T17:27:38Z","timestamp":1724174858000},"page":"e0308913","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Unveiling the potential of phytochemicals to inhibit nuclear receptor binding SET domain protein 2 for cancer: Pharmacophore screening, molecular docking, ADME properties, and molecular dynamics simulation investigations"],"prefix":"10.1371","volume":"19","author":[{"given":"Gamal A.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-7492","authenticated-orcid":true,"given":"Hossam M.","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikhlas A.","family":"Sindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6858-7560","authenticated-orcid":true,"given":"Sabrin R. M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahim A.","family":"Alzain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"3","key":"pone.0308913.ref001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"12","key":"pone.0308913.ref002","doi-asserted-by":"crossref","first-page":"djv273","DOI":"10.1093\/jnci\/djv273","article-title":"Long-term Realism and Cost-effectiveness: Primary Prevention in Combatting Cancer and Associated Inequalities Worldwide","volume":"107","author":"F Bray","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"pone.0308913.ref003","first-page":"23","volume-title":"Disease Control Priorities","author":"F Bray","year":"2015","edition":"3"},{"issue":"3","key":"pone.0308913.ref004","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1021\/acs.jmedchem.0c01768","article-title":"Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2","volume":"64","author":"R Ferreira de Freitas","year":"2021","journal-title":"J Med Chem"},{"issue":"6","key":"pone.0308913.ref005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026708","article-title":"The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.","volume":"7","author":"RL Bennett","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"pone.0308913.ref006","first-page":"25","article-title":"In vitro histone lysine methylation by NSD1, NSD2\/MMSET\/WHSC1 and NSD3\/WHSC1L","volume":"14","author":"M Morishita","year":"2014","journal-title":"BMC Struct Biol"},{"issue":"1","key":"pone.0308913.ref007","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2043-9113-2-18","article-title":"The H-factor as a novel quality metric for homology modeling.","volume":"2","author":"E di Luccio","year":"2012","journal-title":"J Clin Bioinforma."},{"issue":"2","key":"pone.0308913.ref008","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bbrc.2011.07.061","article-title":"Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1","volume":"412","author":"M Morishita","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"pone.0308913.ref009","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbcan.2011.05.004","article-title":"Cancers and the NSD family of histone lysine methyltransferases","volume":"1816","author":"M Morishita","year":"2011","journal-title":"Biochim Biophys Acta\u2014Rev Cancer"},{"issue":"2","key":"pone.0308913.ref010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.15430\/JCP.2015.20.2.113","article-title":"Inhibition of Nuclear Receptor Binding SET Domain 2\/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies","volume":"20","author":"E. di Luccio","year":"2015","journal-title":"J cancer Prev."},{"issue":"1","key":"pone.0308913.ref011","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","article-title":"The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.","volume":"117","author":"E Martinez-Garcia","year":"2011","journal-title":"Blood"},{"issue":"7332","key":"pone.0308913.ref012","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nature09658","article-title":"MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites","volume":"470","author":"H Pei","year":"2011","journal-title":"Nature"},{"issue":"6","key":"pone.0308913.ref013","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1128\/MCB.02130-07","article-title":"Multiple-myeloma-related WHSC1\/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity","volume":"28","author":"JY Kim","year":"2008","journal-title":"Mol Cell Biol"},{"key":"pone.0308913.ref014","doi-asserted-by":"crossref","first-page":"12485","DOI":"10.1038\/srep12485","article-title":"RE-IIBP Methylates H3K79 and Induces MEIS1-mediated Apoptosis via H2BK120 Ubiquitination by RNF20.","volume":"5","author":"J Woo Park","year":"2015","journal-title":"Sci Rep."},{"issue":"5","key":"pone.0308913.ref015","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2217\/epi.15.32","article-title":"The NSD family of protein methyltransferases in human cancer","volume":"7","author":"T Vougiouklakis","year":"2015","journal-title":"Epigenomics"},{"issue":"9","key":"pone.0308913.ref016","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-10-1302","article-title":"The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors","volume":"17","author":"HR Hudlebusch","year":"2011","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"2","key":"pone.0308913.ref017","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/1541-7786.MCR-14-0292-T","article-title":"WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck","volume":"13","author":"V Saloura","year":"2015","journal-title":"Mol Cancer Res"},{"issue":"1","key":"pone.0308913.ref018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1215\/15228517-2007-036","article-title":"Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas.","volume":"10","author":"J Li","year":"2008","journal-title":"Neuro Oncol."},{"issue":"4","key":"pone.0308913.ref019","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.bbrc.2008.12.093","article-title":"MMSET is overexpressed in cancers: link with tumor aggressiveness","volume":"379","author":"A Kassambara","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"pone.0308913.ref020","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1038\/ncomms4630","article-title":"The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes","volume":"5","author":"R Huether","year":"2014","journal-title":"Nat Commun"},{"issue":"45","key":"pone.0308913.ref021","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"S Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"pone.0308913.ref022","doi-asserted-by":"crossref","first-page":"e0197082","DOI":"10.1371\/journal.pone.0197082","article-title":"Identification of a peptide inhibitor for the histone methyltransferase WHSC1.","volume":"13","author":"MJ Morrison","year":"2018","journal-title":"PLoS One."},{"key":"pone.0308913.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.01.002","article-title":"Targeting histone lysine methylation in cancer","volume":"150","author":"J McGrath","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"10","key":"pone.0308913.ref024","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/aps.2016.64","article-title":"Histone lysine methyltransferases as anti-cancer targets for drug discovery.","volume":"37","author":"Q Liu","year":"2016","journal-title":"Acta Pharmacol Sin."},{"issue":"9","key":"pone.0308913.ref025","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts.","volume":"92","author":"M Chesi","year":"1998","journal-title":"Blood"},{"issue":"8","key":"pone.0308913.ref026","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nchembio.1867","article-title":"The promise and peril of chemical probes","volume":"11","author":"CH Arrowsmith","year":"2015","journal-title":"Nat Chem Biol"},{"issue":"11","key":"pone.0308913.ref027","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1021\/acschembio.6b00308","article-title":"Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin Derivatives.","volume":"11","author":"D Tisi","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"3","key":"pone.0308913.ref028","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nsmb.1560","article-title":"Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294","volume":"16","author":"Y Chang","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"pone.0308913.ref029","first-page":"10991","volume-title":"Journal of Medicinal Chemistry","author":"Z Ma","year":"2023"},{"issue":"39","key":"pone.0308913.ref030","first-page":"1083","article-title":"NSD2 momentum.","volume":"6","author":"C. Cain","year":"2013","journal-title":"Sci Exch"},{"issue":"35","key":"pone.0308913.ref031","doi-asserted-by":"crossref","first-page":"13750","DOI":"10.1074\/jbc.RA118.004274","article-title":"High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2","volume":"293","author":"NP Coussens","year":"2018","journal-title":"J Biol Chem"},{"issue":"4","key":"pone.0308913.ref032","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.drudis.2013.07.018","article-title":"Triterpenoids as reversal agents for anticancer drug resistance treatment.","volume":"19","author":"XJ Yan","year":"2014","journal-title":"Drug Discov Today."},{"issue":"8","key":"pone.0308913.ref033","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2174\/18715206113139990301","article-title":"The role of phenolic compounds in the fight against cancer\u2014a review.","volume":"13","author":"M Carocho","year":"2013","journal-title":"Anticancer Agents Med Chem."},{"issue":"2","key":"pone.0308913.ref034","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10616-008-9131-6","article-title":"Evaluation of inhibitory effect and apoptosis induction of Zyzyphus Jujube on tumor cell lines, an in vitro preliminary study","volume":"56","author":"F Vahedi","year":"2008","journal-title":"Cytotechnology"},{"issue":"16","key":"pone.0308913.ref035","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1080\/07391102.2018.1546620","article-title":"Identification of novel urease inhibitors: pharmacophore modeling, virtual screening and molecular docking studies","volume":"37","author":"R Arora","year":"2019","journal-title":"J Biomol Struct Dyn"},{"issue":"15","key":"pone.0308913.ref036","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1080\/07391102.2017.1406824","article-title":"Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer\u2019s disease","volume":"36","author":"S Iqbal","year":"2018","journal-title":"J Biomol Struct Dyn"},{"issue":"10","key":"pone.0308913.ref037","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1080\/07391102.2018.1495576","article-title":"Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors","volume":"37","author":"Y Hu","year":"2019","journal-title":"J Biomol Struct Dyn"},{"issue":"6","key":"pone.0308913.ref038","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/07391102.2017.1329098","article-title":"Identification of type I and type II inhibitors of c-Yes kinase using in silico and experimental techniques","volume":"36","author":"C Ramakrishnan","year":"2018","journal-title":"J Biomol Struct Dyn"},{"issue":"16","key":"pone.0308913.ref039","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1080\/07391102.2017.1415821","article-title":"Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton\u2019s tyrosine kinase inhibitors","volume":"36","author":"S Sakthivel","year":"2018","journal-title":"J Biomol Struct Dyn"},{"key":"pone.0308913.ref040","first-page":"2325","volume-title":"Current topics in medicinal chemistry","author":"MC Monteagudo","year":"2018"},{"issue":"3","key":"pone.0308913.ref041","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.drudis.2018.11.018","article-title":"Computational modeling for formulation design.","volume":"24","author":"CH Mehta","year":"2019","journal-title":"Drug Discov Today"},{"issue":"3","key":"pone.0308913.ref042","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"G Madhavi Sastry","year":"2013","journal-title":"J Comput Aided Mol Des"},{"issue":"6","key":"pone.0308913.ref043","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/ja00214a001","article-title":"The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin","volume":"110","author":"WL Jorgensen","year":"1988","journal-title":"J Am Chem Soc"},{"issue":"2","key":"pone.0308913.ref044","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/ci0503614","article-title":"Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors.","volume":"46","author":"M Rella","year":"2006","journal-title":"J Chem Inf Model."},{"issue":"10","key":"pone.0308913.ref045","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1021\/ci900212v","article-title":"Novel method for generating structure-based pharmacophores using energetic analysis.","volume":"49","author":"NK Salam","year":"2009","journal-title":"J Chem Inf Model."},{"issue":"5","key":"pone.0308913.ref046","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1747-0285.2006.00384.x","article-title":"PHASE: A novel approach to pharmacophore modeling and 3D database searching","volume":"67","author":"SL Dixon","year":"2006","journal-title":"Chem Biol Drug Des"},{"issue":"7","key":"pone.0308913.ref047","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening","volume":"47","author":"TA Halgren","year":"2004","journal-title":"J Med Chem"},{"issue":"7","key":"pone.0308913.ref048","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy","volume":"47","author":"RA Friesner","year":"2004","journal-title":"J Med Chem"},{"key":"pone.0308913.ref049","unstructured":"QikProp, Schr\u00f6dinger, LLC, New York, NY, 2020."},{"key":"pone.0308913.ref050","doi-asserted-by":"crossref","first-page":"100870","DOI":"10.1016\/j.imu.2022.100870","article-title":"Discovery of novel TMPRSS2 inhibitors for COVID-19 using in silico fragment-based drug design, molecular docking, molecular dynamics, and quantum mechanics studies.","volume":"29","author":"AA Alzain","year":"2022","journal-title":"Informatics Med Unlocked."},{"key":"pone.0308913.ref051","doi-asserted-by":"crossref","first-page":"100725","DOI":"10.1016\/j.imu.2021.100725","article-title":"Identification of novel transmembrane Protease Serine Type 2 drug candidates for COVID-19 using computational studies.","volume":"26","author":"FA Elbadwi","year":"2021","journal-title":"Informatics Med Unlocked"},{"issue":"6","key":"pone.0308913.ref052","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1021\/acs.jcim.7b00048","article-title":"Characterizing the Chemical Space of ERK2 Kinase Inhibitors Using Descriptors Computed from Molecular Dynamics Trajectories.","volume":"57","author":"J Ash","year":"2017","journal-title":"J Chem Inf Model."},{"issue":"2","key":"pone.0308913.ref053","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery.","volume":"7","author":"XY Meng","year":"2012","journal-title":"Curr Comput Aided-Drug Des."},{"issue":"4","key":"pone.0308913.ref054","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2174\/138920307781369382","article-title":"Structure-Based Drug Design: Docking and Scoring.","volume":"8","author":"T Romano","year":"2007","journal-title":"Curr Protein Pept Sci."},{"issue":"21","key":"pone.0308913.ref055","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"RA Friesner","year":"2006","journal-title":"J Med Chem"},{"issue":"8","key":"pone.0308913.ref056","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41589-019-0310-x","article-title":"Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3","volume":"15","author":"J B\u00f6ttcher","year":"2019","journal-title":"Nat Chem Biol"},{"issue":"4","key":"pone.0308913.ref057","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hlca.200490082","article-title":"Four New Phenolic Compounds from Curculigo crassifolia (Hypoxidaceae).","volume":"87","author":"N Li","year":"2004","journal-title":"Helv Chim Acta"},{"issue":"6","key":"pone.0308913.ref058","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1055\/s-2002-32555","article-title":"Cytotoxic constituents from Aquilegia ecalcarata","volume":"68","author":"SB Chen","year":"2002","journal-title":"Planta Med"},{"issue":"1\u20133","key":"pone.0308913.ref059","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"CA Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"pone.0308913.ref060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0169-409X(02)00008-X","article-title":"Prediction of drug solubility from structure","volume":"54","author":"WL Jorgensen","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"pone.0308913.ref061","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acs.jctc.7b00028","article-title":"How Molecular Size Impacts RMSD Applications in Molecular Dynamics Simulations.","volume":"13","author":"K Sargsyan","year":"2017","journal-title":"J Chem Theory Comput."},{"issue":"8","key":"pone.0308913.ref062","doi-asserted-by":"crossref","first-page":"e0289887","DOI":"10.1371\/journal.pone.0289887","article-title":"Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.","volume":"18","author":"TH Shoaib","year":"2023","journal-title":"PLoS One."},{"key":"pone.0308913.ref063","article-title":"Computational investigation of binding mechanism of substituted pyrazinones targeting corticotropin releasing factor-1 receptor deliberated for anti-depressant drug design","author":"SM Shashank","year":"2019","journal-title":"J Biomol Struct Dyn"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T17:28:12Z","timestamp":1724174892000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308913"}},"subtitle":[],"editor":[{"given":"Chandrabose","family":"Selvaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":63,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0308913","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]}}}